Zusammenfassung
□ Hintergrund
Stickstoffmonoxid (NO) ist ein gasförmiges, biologisches Effektormolekül mit multiplen Wirkungen. NO wird durch sogenannte NO-Synthasen (NOS) von der semi-essentiellen Aminosäure L-Arginin gebildet. In der Niere spielen die in der Macula densa lokalisierte neuronale NOS (bNOS) und die endotheliale NOS (ecNOS) eine bedeutsame Rolle in der Regulation der glomerulären Hämodynamik. Eine gestörte Funktion dieser beiden Enzyme könnte einen glomerulären Hochdruck und eine gesteigerte intraglomeruläre Thrombozytenaggregation zur Folge haben. Eine NO-Produktion in hohen Gewebekonzentrationen kann durch die induzierbare NOS-Isoform (iNOS) erreicht werden und scheint hingegen ein potenter Inflammationsmediator bei primär entzündlichen Nierenerkrankungen zu sein. Die selektive Hemmung der iNOS könnte zukünftig ein neues, antiinflammatorisches Therapieprinzip zum Beispiel in der Glomerulonephritisbehandlung werden. Im folgenden soll anhand von überwiegend experimentellen Daten die Bedeutung von NO, aber auch anderer Metaboliten der Aminosäure L-Arginin, für die Pathophysiologie und therapeutische Beeinflussung von Nierenkrankheiten dargestellt werden.
□ Schlußfolgerung
Die Modulation des renalen L-Arginin/NO-Systems repräsentiert einen vielversprechenden Therapieansatz bei akuten und chronischen Nierenkrankheiten.
Summary
□ Background
Nitric oxide (NO) is a small gaseous, molecule with multiple biological effects. NO is produced from the semi-essential amino acid L-arginine by NO synthases (NOS). In the kidney, neuronal NOS (bNOS), which is localized in the macula densa, and endothelial NOS (ec NOS) are involved in the regulation of glomerular hemodynamics. Dysfunction of these enzymes may cause glomerular hypertension and increased intraglomerular platelet aggregation. NO production in high tissue concentrations can be achieved by activation of an inducible NOS isoform (iNOS) and may act as a potent mediator of inflammation in immune-mediated renal diseases. Selective inhibition of iNOS may, therefore, become a novel anti-inflammatory approach in the treatment of glomerulonephritis. Based on experimental data, the potential importance of NO and other metabolites of L-arginine in the pathophysiology and therapy of renal diseases is summarized in this article.
□ Conclusion
Modulation of the renal L-arginine/NO-system represents a promising therapeutic target in the treatment of acute an chronic kidney diseases.
Literatur
Albina, J. E., C. D. Mills, A. Barbul, C. E. Thirkill, W. L. Henry Jr, B. Mastrofrancesco, M. D. Caldwell: Arginine metabolism in wounds. Amer. J. Physiol. 254 (1988), E459-E467.
Albina, J. E., C. D. Mills, W. L. Henry Jr, M. D. Caldwell: Temporal expression of different pathways of L-arginine metabolism in healing wounds. J. Immunol. 144 (1990), 3877–3880.
Bachmann, S., P. Mundel: Nitric oxide synthase in the kidney: synthesis, localization and function. Amer. J. Kidney Dis. 24 (1994), 112–129.
Border, W. A., N. A. Noble: Transforming growth factor-β in tissue fibrosis. New Engl. J. Med. 331 (1994), 1286–1292.
Cattell, V., H. T. Cook: Nitric oxide: role in the physiology and pathology of the glomerulus. Exp. Nephrol. 1 (1993), 265–280.
Cattell, V., H. T. Cook, S. Moncada: Glomeruli synthesize nitrite in experimental nephrotoxic nephritis. Kidney int. 38 (1990), 1056–1060.
Cattell, V., P. Largen, E. DeHeer, T. Cook: Glomeruli synthesize nitrite in active Heyman nephritis: the source is infiltrating macrophages. Kidney int. 40 (1991), 847–851.
Cattell V., E. Lianos, P. Largen, T. Cook: Glomerular NO synthase activity in mesangial cell immune injury. Exp. Nephrol. 1 (1993), 36–40.
Chen, P. Y., P. L. St. John, K. A. Kirk, D. R. Abrahamson, P. W. Sanders: Hypertensive nephrosclerosis in the Dahl/Rapp rats. Lab. Invest. 68 (1993), 174–184.
Cook, H. T., H. Ebrahim, A. S. Jansen, G. R. Foster, P. Largen, V. Cattell: Expression of the gene for inducible nitric oxide synthase in experimental glomerulonephritis in the rat. Clin. exp. Immunol. 97 (1994), 315–320.
Cook, H. T., A. Jansen, S. Lewis, P. Largen, M. O’Donnell, D. Reaveley, V. Cattell: Arginine metabolism in experimental glomerulonephritis: interaction between nitric oxide synthase and arginase. Amer. J. Physiol. 267 (1994), F646-F653.
Cook, H. T., R. S. Sullivan: Glomerular nitrite synthesis in in situ immune complex glomerulonephritis in the rat. Amer. J. Pathol. 139 (1991), 1047–1052.
De Nicola, L., R. C. Blantz, F. B. Gabbai: Nitric oxide and angiotensin II. J. clin. Invest. 89 (1992), 1248–1256.
De Nicola, L., S. C. Thomson, L. M. Wead, M. R. Brown, F. B. Gabbai: Arginine feeding modifies cyclosporine nephrotoxicity in rats. J. clin. Invest. 92 (1993), 1859–1865.
Ferrario, R., K. Takahashi, A. Fogo, K. F. Badr, K. A. Munger: Consequences of acute nitric oxide synthesis inhibition in experimental glomerulonephritis. J. Amer. Soc. Nephrol. 4 (1994), 1847–1854.
Furchgott, R. F., J. V. Zawadski: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (Lond.) 288 (1980), 373–376.
Glicklich, D., L. Swartz, N. Bank: Nitric oxide metabolites in acute renal allograft rejection. J. Amer. Soc. Nephrol. 6 (1995), 1087 (abstract).
Hibbs, J. B., Jr, R. R. Taintor, Z. Vavrin: Macrophage cytotoxicity: role for L-arginine deaminase and imino nitrogen oxidation to nitrate. Science 235 (1987), 473–476.
Hibbs, J. B. Jr, R. R. Taintor, Z. Vavrin, E. M. Rachlin: Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. biophys. Res. Commun. 157 (1988), 87–94.
Höltta, E., M. Auvinen, L. C. Andersson: Polyamines are essential for cell transformation by pp60v-src: Delineation of molecular events relevant for the transformed phenotype. J. Cell Biol. 122 (1993), 903–914.
Ignarro, L. J., G. M. Buga, K. S. Wood, R. E. Byrne, G. Chaudhuri: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. nat. Acad. Sci. (Wash.) 84 (1987), 9265–9269.
Ito, S., O. A. Carretero, K. Abe: Nitric oxide in the juxtaglomerular apparatus. Kidney int. 49, Suppl. 55 (1996), S6-S8.
Jänne, O. A., K. K. Kontula, V. V. Isomaa, C. W. Bardin: Ornithine decarboxylase in mouse kidney: a low abundancy gene product, regulated by androgens with rapid kinetics. Ann. N. Y. Acad. Sci. 438 (1984), 72–84.
Jansen, A., T. Cook, G. M. Taylor, P. Largen, V. Riveros-Moreno, S. Moncada, V. Cattell: Induction of nitric oxide synthase in rat immune complex glomerulonephritis. Kidney int. 45 (1994), 1215–1219.
Ketteler, M., F. Abou-Rebyeh, H. Peters, R. Langhoff, N. Noble, W. Border, A. Distler: Die Bedeutung von Polyaminen für die TGF-β-induzierte Fibronektinsynthese kultivierter Mesangiumzellen der Ratte (RMZ). Nieren- u. Hochdruckkr. 9 (1995), 535–536 (abstract).
Ketteler, M., W. A. Border, N. A. Noble: Cytokines and L-arginine in renal injury and repair. Amer. J. Physiol. 267 (1994), F197-F207.
Ketteler, M., D. K. Brees, W. A. Border, N. A. Noble: Inhibition of polyamine synthesis reduces TGF-β-induced hypertrophy of cultured rat mesangial cells. J. Amer. Soc. Nephrol. 5 (1994), 694 (abstract).
Ketteler, M., N. Ikegaya, D. K. Brees, W. A. Border, N. A. Noble. L-arginine metabolism in immune-mediated glomerulonephritis in the rat. Amer. J. Kidney Dis. 28 (1996), 878–887.
Ketteler, M., N. A. Noble, W. A. Border: Increased expression of transforming growth factor-β in renal disease. Curr. Opin. Nephrol. Hypertens. 3 (1994), 446–452.
Knowles, R. G., S. Moncada: Nitric oxide synthases in mammals. Biochem. J. 298 (1994), 249–258.
Langrehr, J. M., R. A. Hoffinan, J. R. Lancaster Jr, R. L. Simmons: Nitric oxide — a new endogenous immunomodulator. Transplantation 55 (1993), 1205–1212.
Li, G., S. Regunathan, C. J. Barrow, J. Esharaghi, R. Copper, D. J. Reis: Agmatine, an endogenous clonidin-replacing substance in the brain. Science 263 (1994), 966–969.
Lortie, M. J., W. F. Novotny, O. W. Peterson, V. Vallon, K. Malvey, M. Mendonca, J. Satriano, P. Insel, S. C. Thompson, R. C. Blantz: Agmatine, a bioactive metabolite of arginine. J. clin. Invest. 97 (1996), 413–420.
Lowenstein, C. J., J. L. Dinerman, S. H. Snyder: Nitric oxide: a physiological messenger. Ann. intern. Med. 120 (1994), 227–237.
Marletta, M. A.: Nitric oxide synthase structure and mechanism. J. biol. Chem. 268 (1993), 12231–12234.
Marsden, P. A., B. J. Ballermann: Tumor necrosis factor α activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. J. exp. Med. 172 (1990), 1843–1852.
Moncada, S., H. Higgs: The L-arginine-nitric oxide pathway. New Engl. J. Med. 329 (1993), 2002–2012.
Moncada, S., R. M. J. Palmer, E. A. Higgs Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacol. Rev. 43 (1991), 109–143.
Morrissey J., U. Alvarez, N. Kizer, S. Klahr: Agmatine activates nitric oxide synthase in endothelial cells. J. Amer. Soc. Nephrol. 6 (1995), 665 (abstract).
Narita, I., W. A. Border, M. Ketteler, N. A. Noble: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab. Invest. 72 (1995), 17–24.
Narita, I., W. A. Border, M. Ketteler, E. Ruoslahti, N. A. Noble: L-arginine may mediate the therapeutic effects of low protein diets. Proc. nat. Acad. Sci. (Wash.) 92 (1995), 4552–4556.
Nathan, C.: Nitric oxide as a secretory product of mammalian cells. FASEB J. 6 (1992), 3051–3064.
Nathan, C., Q.-W. Xie: Regulation of biosynthesis of nitric oxide. J. biol. Chem. 269 (1994), 13725–13728.
Palmer, R. M. J., A. J. Ferrige, S. Moncada: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond.) 327 (1987), 524–526.
Pegg, A. E.: Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res. 48 (1988), 759–774.
Pfeilschifter, J., D. Kunz, H. Mühl: Nitric oxide: an inflammatory mediator of glomerular mesangial cells. Nephron 64 (1993), 518–525.
Raij, L., C. Baylis: Glomerular actions of nitric oxide. Kidney int. 48 (1995), 20–32.
Reyes, A. A., I. Karl, S. Klahr: Role of arginine in health and in renal disease. Amer. J. Physiol. 267 (1994), F331-F346.
Reyes, A. A., M. L. Purkerson, I. Karl, S. Klahr: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Amer. J. Kidney Dis. 20 (1992), 168–176.
Satriano, J., M. Lortie, C. J. Kelly, R. C. Blantz: Nitric oxide synthase (iNOS) activity is regulated by the arginine decarboxylase (ADC) pathway. J. Amer. Soc. Nephrol. 6 (1995), 669 (abstract).
Satriano, J., M. Lortie, V. Vallon, C. J. Kelly, R. C. Blantz: Ornithine decarboxylase (ODC) activity is regulated by agmatine. J. Amer. Soc. Nephrol. 6 (1995), 775 (abstract).
Shih, V. E.: Regulation of ornithine metabolism. Enzyme 26 (1978), 254–258.
Weinberg, J. B., D. L. Granger, D. S. Pisetzky, M. F. Seldin, M. A. Misukonis, S. N. Mason, A. M. Pippen, P. Ruiz, E. R. Wood, G. S. Gilkeson: The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J. exp. Med. 179 (1994), 651–660.
Worrall, N. K., W. D. Lazenby, T. P. Misko, T. S. Lin, C. P. Rodi, P. T. Manning, R. G. Tilton, J. R. Williamson, T. B. Ferguson Jr: Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J. exp. Med. 181 (1995), 63–70.
Yang, X., N. Chowdury, B. Cai, J. Brett, C. Marboe, R. R. Scianca R. E. Michler, P. J. Cannon: Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J. clin. Invest. 94 (1994), 714–721.
Yu, L., P. E. Gengaro, M. Niederberger, T. J. Burke, R. W. Schrier: Nitric oxide: a mediator in rat tubular hypoxia/reoxygenation injury. Proc. nat. Acad. Sci. (Wash.) 91 (1994), 1691–1695.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ketteler, M., Abou-Rebyeh, F., Frey, A. et al. Stickstoffmonoxid, L-Arginin und die Niere. Med. Klin. 93, 15–21 (1998). https://doi.org/10.1007/BF03045035
Issue Date:
DOI: https://doi.org/10.1007/BF03045035